PPARG and type 2 diabetes mellitus: In this microarray experiment, peroxisome proliferator-activated receptor type γ (PPARγ), which plays important roles in atherogenesis and is a molecular target for pharmaceutical products such as Avandia® for treating cardiovascular complication among type 2 diabetic patients (GlaxoSmith Kline, Inc.), was found to be highly upregulated by OxLDL and naïve LDL during the macrophage differentiation to foam cells.